[Combined immunomodulating therapy in rheumatoid arthritis]

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
• Methotrexate (MT) is a common disease-modifying antirheumatic drug (DMARD) used as a first-line treatment for RA.
• Tactivin (T) is a potential immunomodulatory agent explored for autoimmune conditions.

Purpose of the Study:

• To compare the efficacy and safety of methotrexate monotherapy versus combination therapy with methotrexate and tactivin in patients with rheumatoid arthritis.
• To evaluate the impact of combined therapy on disease activity, pain, and inflammatory markers.

Main Methods:

• A 2-year clinical trial involving 127 patients with rheumatoid arthritis.
• Patients were randomized to receive either methotrexate (7.5 mg weekly) monotherapy (n=88) or methotrexate plus subcutaneous tactivin (100 mcg twice weekly for one month, then weekly) (n=39).
• Disease severity, joint inflammation, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were monitored.

Main Results:

• Both treatment groups showed significant reductions in arthralgia severity, inflamed joints, CRP levels, and ESR.
• The combination therapy group (MT+T) achieved significant improvements in morning stiffness and joint pain upon palpation.
• Adverse events were comparable between the monotherapy and combination therapy groups.

Conclusions:

• Combination therapy with methotrexate and tactivin offers additional benefits in managing rheumatoid arthritis symptoms, including morning stiffness and pain.
• Methotrexate and tactivin combination therapy demonstrates a favorable safety profile, comparable to methotrexate monotherapy.
• Further research may explore the long-term efficacy and specific mechanisms of tactivin in RA treatment.